This move is archived. Current quotes and coverage live on the stock page.
Follow WAVE
Waverley Pharma Inc's stock took a significant hit, dropping 25% in a single trading session.
Waverley Pharma Inc (WAVE.V) experienced a sharp decline in its stock price yesterday, closing at CA$0.01. This drop of 25% raises concerns among investors regarding the company's financial health and future prospects.
Waverley Pharma Inc
WAVE.V
WAVE.V
Waverley Pharma Inc
WealthAwesomeMarket cap
$540,000
52W high
$0.03
52W low
$0.01
1W change
+100.00%
Beta
1.46
Analyst Price Targets
Based on analyst covering WAVE · as of Sep 17, 2026
Wall Street analysts forecast WAVE stock price to rise 49900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.00
+49900.0% Upside
Current Price
C$0.02
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on WAVE's historical volatility
30-Day Vol
518.1%
Annualized
90-Day Vol
520.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.00 – C$0.13 |
| 60 trading days | C$0.02 | C$0.00 – C$0.28 |
| 90 trading days | C$0.02 | C$0.00 – C$0.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Waverley Pharma's financial stability, especially in light of recent leadership changes and auditor concerns.
Waverley Pharma's market cap now stands at just CA$810,000.
With a market cap this low and a P/E ratio of 0, the stock's valuation reflects significant investor skepticism.
Bull case
Despite the recent downturn, Waverley Pharma's acquisition of C & R Pharmacy could improve its market position and revenue in the long run. This move might help the company tap into new customer bases and enhance its overall business strategy.
Bear case
The resignation of the CFO and the auditor's doubts about the company's ability to continue as a going concern present serious challenges for Waverley Pharma. These issues raise red flags for investors, who may be concerned about the company's future viability.
Recent Performance Overview
Waverley Pharma's stock fell sharply yesterday, dropping 25% to close at CA$0.01. This significant decline is alarming for investors, especially considering the company's already precarious financial standing.
Factors Contributing to the Decline
The recent resignation of the Chief Financial Officer and the auditor's expressed doubts about the company's ability to continue as a going concern have likely contributed to the negative sentiment surrounding Waverley Pharma. Investors are understandably wary given these developments.
Looking Ahead
As Waverley Pharma navigates these challenges, investors should keep a close watch on upcoming announcements and financial reports. The company's acquisition of C & R Pharmacy may provide a glimmer of hope, but the risks remain high.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
